AbbVie Inc. (ABBV) Bundle
A Brief History of AbbVie Inc.
AbbVie Inc., a global biopharmaceutical company, was founded in 2013 as a spin-off from Abbott Laboratories. The company focuses on advanced therapies for complex diseases, including immunology, oncology, and neuroscience. By 2024, AbbVie has established a significant presence in the pharmaceutical industry with a diverse product portfolio and a strong commitment to research and development.
Financial Performance Overview
As of September 30, 2024, AbbVie reported net earnings attributable to the company of $4.3 billion, compared to $4.0 billion in the same period of the previous year. The earnings per share (EPS) were $2.41 for the nine months ended September 30, 2024, compared to $2.27 for the same period in 2023.
| Financial Metrics | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Net Earnings (in millions) | $4,300 | $4,041 |
| Basic EPS | $2.41 | $2.27 |
| Operating Activities Cash Flow (in millions) | $11,758 | $18,086 |
| Investing Activities Cash Flow (in millions) | ($18,946) | ($1,209) |
| Financing Activities Cash Flow (in millions) | $1,650 | ($12,773) |
Major Acquisitions
In 2024, AbbVie completed several significant acquisitions, including:
- Acquisition of Cerevel Therapeutics on August 1, 2024, for $8.7 billion.
- Announcement of the proposed acquisition of Aliada Therapeutics on October 28, 2024, with an upfront cash payment of approximately $1.4 billion.
Research and Development Expenditure
AbbVie has consistently invested in research and development, with R&D expenses amounting to $6.0 billion for the nine months ended September 30, 2024, up from $5.7 billion in 2023. This reflects a commitment to enhancing its pipeline of innovative therapies.
| R&D Expenditure (in millions) | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Total R&D Expenses | $6,017 | $5,748 |
Debt and Liquidity Position
As of September 30, 2024, AbbVie reported total liabilities of $143.4 billion, with total stockholders' equity of $6.1 billion. The company's long-term debt was $58.5 billion, reflecting its strategy to finance acquisitions and operations through debt instruments.
| Debt Metrics | 2024 |
|---|---|
| Total Liabilities (in billions) | $143.4 |
| Long-term Debt (in billions) | $58.5 |
Stock Performance
AbbVie’s stock performance reflects its growth trajectory, with a share price increase of approximately 5.8% following the announcement of its latest quarterly dividend increase to $1.64 per share, effective February 14, 2025.
| Stock Performance Metrics | Value |
|---|---|
| Recent Share Price Increase (%) | 5.8% |
| Quarterly Dividend per Share | $1.64 |
Conclusion
AbbVie continues to strengthen its market position through strategic acquisitions, robust R&D investments, and effective financial management. The company’s focus on innovation and growth is evident in its financial performance and commitment to advancing healthcare solutions.
A Who Owns AbbVie Inc. (ABBV)
Major Shareholders
As of 2024, AbbVie Inc. has a diverse ownership structure comprising institutional investors, mutual funds, and insiders. The following table summarizes the major shareholders of AbbVie Inc.:
| Shareholder Type | Number of Shares Owned (millions) | Percentage of Ownership |
|---|---|---|
| Vanguard Group | 223 | 12.6% |
| BlackRock, Inc. | 215 | 12.1% |
| State Street Corporation | 133 | 7.5% |
| Fidelity Investments | 107 | 6.0% |
| Invesco Ltd. | 86 | 4.8% |
| Other Institutions | 600 | 33.7% |
| Insiders | 11 | 0.6% |
| Public Float | 546 | 30.9% |
Institutional Ownership
Institutional investors hold a significant portion of AbbVie’s shares, reflecting confidence in the company’s growth strategy and financial performance. As of September 30, 2024, institutional ownership was approximately 67% of the total shares outstanding.
Insider Ownership
Insiders of AbbVie, including executives and board members, own approximately 0.6% of the company’s shares. This includes stock options and restricted stock units. The following table illustrates the top executives and their respective holdings:
| Executive Name | Position | Shares Owned (millions) |
|---|---|---|
| Richard A. Gonzalez | Chairman & CEO | 2.3 |
| Holly A. B. Garrison | Chief Financial Officer | 0.5 |
| Michael Severino | President | 0.8 |
| Other Executives | - | 7.4 |
Stock Performance and Market Capitalization
As of October 28, 2024, AbbVie’s market capitalization was approximately $250 billion, with stock trading at around $141.19 per share. The stock has shown resilience, with a year-to-date performance increase of 15%.
Recent Acquisitions Impacting Ownership
In August 2024, AbbVie completed the acquisition of Cerevel Therapeutics for approximately $8.7 billion, which has influenced its stock performance and market perception. This strategic acquisition aims to enhance AbbVie’s neuroscience portfolio.
Dividends and Shareholder Returns
AbbVie has a strong history of returning capital to shareholders through dividends. The quarterly dividend was increased to $1.64 per share, reflecting a 5.8% increase from the previous quarter. Dividend payments for the nine months ended September 30, 2024, totaled approximately $8.3 billion.
| Quarter | Dividend Declared | Payment Date |
|---|---|---|
| Q1 2024 | $1.55 | May 15, 2024 |
| Q2 2024 | $1.55 | August 15, 2024 |
| Q3 2024 | $1.55 | November 15, 2024 |
| Q4 2024 | $1.64 | February 14, 2025 |
Conclusion on Ownership Structure
The ownership of AbbVie Inc. is characterized by significant institutional holdings, a modest insider ownership, and a strong commitment to shareholder returns through dividends and stock repurchases. The company's strategic acquisitions and solid financial performance continue to attract investor interest.
AbbVie Inc. (ABBV) Mission Statement
Mission Overview
AbbVie Inc. aims to discover and develop innovative medicines and products that address serious health issues today and tackle the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution. The company focuses on maximizing the benefits of a diversified revenue base with multiple long-term growth drivers.
Strategic Objectives
- Leverage AbbVie's commercial strength and international infrastructure across therapeutic areas.
- Ensure strong commercial execution of new product launches.
- Invest in and expand its pipeline in immunology, oncology, aesthetics, neuroscience, and eye care.
- Generate substantial operating cash flows to support innovative research and development.
- Return cash to shareholders via a strong and growing dividend while continuing to repay debt.
Financial Performance (2024)
For the nine months ended September 30, 2024, AbbVie reported:
| Metric | Value (in millions) |
|---|---|
| Worldwide Net Revenues | $41,232 |
| Operating Earnings | $10,627 |
| Diluted Earnings Per Share | $2.41 |
| Cash Flows From Operations | $11,758 |
Revenue Breakdown
AbbVie’s net revenues for the three months ended September 30, 2024, by product line:
| Product | U.S. Sales (in millions) | International Sales (in millions) | Total Sales (in millions) |
|---|---|---|---|
| Humira | $1,765 | $462 | $2,227 |
| Skyrizi | $2,778 | $427 | $3,205 |
| Rinvoq | $1,170 | $444 | $1,614 |
| Imbruvica | $618 | $210 | $828 |
| Venclexta | $340 | $337 | $677 |
| Botox Cosmetic | $414 | $257 | $671 |
Research and Development Focus
AbbVie’s pipeline includes approximately 90 compounds, devices, or indications in various stages of development. Key areas of focus include:
- Immunology
- Oncology
- Aesthetics
- Neuroscience
- Eye care
Recent Acquisitions and Investments
AbbVie has made significant acquisitions to enhance its portfolio:
- Acquisition of ImmunoGen for $17.5 billion.
- Acquisition of Cerevel Therapeutics for $8.7 billion.
- Acquisition of Celsius Therapeutics for $250 million.
As of September 30, 2024, AbbVie’s total assets were valued at $143.4 billion, with long-term debt totaling $58.5 billion.
How AbbVie Inc. (ABBV) Works
Business Model
AbbVie Inc. operates as a global biopharmaceutical company, focusing on the discovery, development, manufacturing, and marketing of advanced therapies. The company is structured around various therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care.
Financial Performance
For the nine months ended September 30, 2024, AbbVie reported worldwide net revenues of $41.2 billion, representing a 3% increase compared to the same period in 2023. The operating earnings reached $10.6 billion, and the diluted earnings per share (EPS) stood at $2.41.
| Financial Metric | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| Net Revenues | $41.2 billion | $40.0 billion |
| Operating Earnings | $10.6 billion | $9.6 billion |
| Diluted EPS | $2.41 | $2.27 |
| Cash Flows from Operations | $11.8 billion | $18.1 billion |
Revenue Breakdown by Product
AbbVie’s revenue sources are diversified across several key products. For the three months ended September 30, 2024, the following revenue figures were reported:
| Product | U.S. Revenue (Q3 2024) | International Revenue (Q3 2024) | Total Revenue (Q3 2024) |
|---|---|---|---|
| Humira | $1.8 billion | $462 million | $2.2 billion |
| Skyrizi | $2.8 billion | $427 million | $3.2 billion |
| Rinvoq | $1.2 billion | $444 million | $1.6 billion |
| Imbruvica | $618 million | $210 million | $828 million |
| Venclexta | $340 million | N/A | $340 million |
Research and Development
AbbVie invests heavily in research and development (R&D), focusing on innovative therapies. The company has around 90 compounds in its pipeline, with approximately 50 in mid- and late-stage development.
Debt and Financing
As of September 30, 2024, AbbVie reported total long-term debt of $58.5 billion, which includes a recent issuance of $15 billion in senior notes to finance acquisitions. The company’s interest expense for the nine months ended September 30, 2024, was $1.6 billion.
| Debt Issuance | Amount (in millions) |
|---|---|
| Senior Notes (2027) | $2,250 |
| Senior Notes (2029) | $2,500 |
| Senior Notes (2031) | $2,000 |
| Senior Notes (2034) | $3,000 |
| Senior Notes (2044) | $750 |
| Senior Notes (2054) | $3,000 |
| Senior Notes (2064) | $1,500 |
| Total Debt Issued | $15,000 |
Stock Performance and Dividends
AbbVie has a history of returning value to shareholders through dividends. The company declared a quarterly cash dividend of $1.55 per share for the third quarter of 2024, with an increase to $1.64 per share announced for the first quarter of 2025.
| Dividend Declaration | Payment Date | Dividend Per Share |
|---|---|---|
| October 30, 2024 | February 14, 2025 | $1.64 |
| September 6, 2024 | November 15, 2024 | $1.55 |
| June 21, 2024 | August 15, 2024 | $1.55 |
| February 15, 2024 | May 15, 2024 | $1.55 |
Recent Acquisitions
In 2024, AbbVie completed the acquisition of Cerevel Therapeutics for approximately $8.7 billion and entered into an agreement to acquire Aliada Therapeutics for about $1.4 billion.
How AbbVie Inc. (ABBV) Makes Money
Revenue Streams
AbbVie Inc. generates revenue primarily through the sale of pharmaceutical products across various therapeutic areas, including immunology, oncology, aesthetics, and neuroscience. The company reported worldwide net revenues of $41.2 billion for the nine months ended September 30, 2024, representing a 3% increase year-over-year at actual currency rates.
| Therapeutic Area | Product Name | Q3 2024 Revenue (in millions) | Q3 2023 Revenue (in millions) | Change (%) |
|---|---|---|---|---|
| Immunology | Humira | $2,227 | $3,547 | (37.2) |
| Immunology | Skyrizi | $3,205 | $2,126 | 50.8 |
| Immunology | Rinvoq | $1,614 | $1,110 | 45.3 |
| Oncology | Imbruvica | $828 | $908 | (8.8) |
| Oncology | Venclexta | $677 | $590 | 14.7 |
| Aesthetics | Botox Cosmetic | $671 | $620 | 8.2 |
| Neuroscience | Vraylar | $875 | $751 | 16.5 |
Product Performance
The flagship product, Humira, has seen a significant decline in sales due to biosimilar competition, with U.S. revenues dropping by 41.6% in Q3 2024 compared to Q3 2023. In contrast, newer products like Skyrizi and Rinvoq have demonstrated strong growth, with Skyrizi's U.S. sales increasing by 48.3%.
Research and Development Investments
AbbVie heavily invests in research and development (R&D) to sustain its pipeline, which currently includes approximately 90 compounds in various stages of development. R&D expenses for the nine months ended September 30, 2024, amounted to $1.2 billion.
Cost Structure
AbbVie's total operating costs and expenses for the nine months ended September 30, 2024, were $30.6 billion, leading to operating earnings of $10.6 billion. The company's gross margin improved to 71% in Q3 2024, compared to 53% in Q3 2023, reflecting better product mix and pricing strategies.
Acquisitions and Collaborations
AbbVie has pursued strategic acquisitions to bolster its portfolio. In 2024, AbbVie completed the acquisition of Cerevel Therapeutics for approximately $8.7 billion. Additionally, it entered into a definitive agreement to acquire Aliada Therapeutics for $1.4 billion, focusing on Alzheimer’s disease treatments.
Cash Flow and Dividends
AbbVie reported cash flows from operations of $11.8 billion for the nine months ended September 30, 2024. The company has maintained a strong dividend policy, declaring total cash dividends of $8.3 billion during the same period. The quarterly dividend was recently increased to $1.64 per share.
Market Position and Future Outlook
AbbVie’s strategic focus on diversifying its revenue base and advancing its pipeline positions it well for future growth. The company anticipates significant contributions from its newer therapies, which are expected to mitigate the impact of declining Humira sales.
AbbVie Inc. (ABBV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- AbbVie Inc. (ABBV) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of AbbVie Inc. (ABBV)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View AbbVie Inc. (ABBV)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.